In vitro characteristics of Epirubicin-loaded thermosensitive liquid embolic agent

J Cancer Res Ther. 2023 Dec 1;19(6):1597-1602. doi: 10.4103/jcrt.jcrt_334_23. Epub 2023 Dec 28.

Abstract

Objective: To investigate the drug loading and release rate of epirubicin-loaded thermosensitive liquid embolic agents in vitro.

Materials and methods: The drug loading and stability of epirubicin-loaded thermosensitive liquid embolic agents with or without iopromide were determined by high-performance liquid chromatography, and the same method was used to determine the drug release rate of thermosensitive liquid embolic agents at different time points.

Results: For epirubicin-loaded thermosensitive liquid embolic agents without iopromide, the average drug loading after filtration by membrane was (0.78 ± 0.02) mg and the drug loading rate was (16.1 ± 0.35)%, while the average drug loading without membrane was (0.73 ± 0.06) mg and the drug loading rate was (15.07 ± 1.17)%. After adding iopromide, the drug loading capacity was measured from 0 h-24 h solution and the drug loading was calculated indirectly and conclude that the drug loading capacity of thermosensitive liquid embolic agents decreased or disappeared. The sustained release rate of epirubicin from 0 to 48 hours was 42.65% in 48 hours.

Conclusion: Epirubicin can be successfully loaded into the thermosensitive liquid embolic agents with good stability and sustained release. After adding iopromide, the drug loading capacity of thermosensitive liquid embolic agents decreased or disappeared.

MeSH terms

  • Delayed-Action Preparations
  • Drug Liberation
  • Epirubicin
  • Humans
  • Iohexol*

Substances

  • Epirubicin
  • Delayed-Action Preparations
  • iopromide
  • Iohexol